Phase II Study of Oral S-1 Plus Irinotecan in Patients With Advanced Gastric Cancer

Sponsor
Hokkaido Gastrointestinal Cancer Study Group
Study ID
NCT00209664
Phase
PHASE2
Status
Suspended

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

To assess the usefulness of irinotecan plus S-1 therapy based on the antitumor effect and survival period. by performing a phase II study of this combination in patients with inoperable or with postoperative gastric cancer

Key Dates

Start date
Jan 31, 2004
Status verified
Jan 2004
Completion
Dec 31, 2008

Study Design

Enrollment
40 participants
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

objective tumor response

Related Studies